Press Release

Kirkland Counsels Boehringer Ingelheim on Alliance with Lilly

Kirkland & Ellis advised Boehringer Ingelheim on its amended and restated alliance agreement with Eli Lilly and Company (NYSE: LLY).  The parties agreed to modernize their alliance and focus their combined expertise and investment on the continued development and commercialization of Jardiance® (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease. Trajenta® (linagliptin) and Basaglar® (insulin glargine) continue to be part of the alliance, but on revised terms.

Read the Lilly press release

The Kirkland team was led by technology and IP transactions partner David MacDonald and associate Matt Darch.